The short version
Just 3 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
olmesartan medoxomil-hydrochlorothiazide
olmesartan medoxomil-hydrochlorothiazide · OLMESARTAN MEDOXOMIL 40 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1 · Tablet, Film Coated · Oral · AvKARE
NDC 42291-0926-90 · 90 TABLET, FILM COATED in 1 BOTTLE · NDA · View full market →
Medicare Part D
All Part D pricing →Matched to CMS's representative package for this drug (NDC 00713-0865-30) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
ⓘ How this was built
Data sources
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Plans pay at point of saleⓘ
$15.95per unit
middle half $15.95–$15.95 · 2 plans · Apr 1, 2026
Est. net of rebatesⓘ
$9.57–$11.96
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
0%of plans cover it
tier 1 · prior auth 0% · step therapy 0% · qty limit 100%
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$721.60
Reported to Texas DSHS · 2026 annual filing · AvKare
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.2%chance of a new FDA shortage posting for olmesartan medoxomil and hydrochlorothiazide (oral solid) in the next 90 days
OAI inspection at a producing facility (24 months) · sole-source market · price up 4% YoY
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Regulatory
- Application
- NDA021532
- TE code
- AB
- Approval date
- Jun 5, 2003
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of olmesartan medoxomil-hydrochlorothiazide (Tablet, Film Coated)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| AvKARE | OLMESARTAN MEDOXOMIL 40 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1 | Aug 26, 2026 | Sep 3, 2026 |
| AvKARE | OLMESARTAN MEDOXOMIL 40 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1 | Aug 26, 2026 | Sep 3, 2026 |
| Cosette Pharmaceuticals, Inc. | OLMESARTAN MEDOXOMIL 40 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1 | Aug 26, 2026 | Sep 3, 2026 |
| Cosette Pharmaceuticals, Inc. | OLMESARTAN MEDOXOMIL 20 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1 | Aug 26, 2026 | Sep 3, 2026 |
| Novadoz Pharmaceuticals LLC | OLMESARTAN MEDOXOMIL 40 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Novadoz Pharmaceuticals LLC | OLMESARTAN MEDOXOMIL 40 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Novadoz Pharmaceuticals LLC | OLMESARTAN MEDOXOMIL 20 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| AvKARE | OLMESARTAN MEDOXOMIL 20 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1 | Aug 26, 2026 | Aug 31, 2026 |
| Cosette Pharmaceuticals, Inc. | OLMESARTAN MEDOXOMIL 40 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1 | Aug 26, 2026 | Aug 31, 2026 |
| AvKARE | OLMESARTAN MEDOXOMIL 12.5 mg/1; HYDROCHLOROTHIAZIDE 40 mg/1 | Jul 22, 2026 | Aug 22, 2026 |
| Cosette Pharmaceuticals, Inc. | OLMESARTAN MEDOXOMIL 12.5 mg/1; HYDROCHLOROTHIAZIDE 20 mg/1 | Jul 22, 2026 | Aug 22, 2026 |
| Cosette Pharmaceuticals, Inc. | OLMESARTAN MEDOXOMIL 12.5 mg/1; HYDROCHLOROTHIAZIDE 40 mg/1 | Jul 22, 2026 | Aug 22, 2026 |
| AvKARE | OLMESARTAN MEDOXOMIL 25 mg/1; HYDROCHLOROTHIAZIDE 40 mg/1 | Jul 22, 2026 | Aug 21, 2026 |
| AvKARE | OLMESARTAN MEDOXOMIL 12.5 mg/1; HYDROCHLOROTHIAZIDE 20 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Cosette Pharmaceuticals, Inc. | OLMESARTAN MEDOXOMIL 25 mg/1; HYDROCHLOROTHIAZIDE 40 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Novadoz Pharmaceuticals LLC | OLMESARTAN MEDOXOMIL 12.5 mg/1; HYDROCHLOROTHIAZIDE 20 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Novadoz Pharmaceuticals LLC | OLMESARTAN MEDOXOMIL 12.5 mg/1; HYDROCHLOROTHIAZIDE 40 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Novadoz Pharmaceuticals LLC | OLMESARTAN MEDOXOMIL 25 mg/1; HYDROCHLOROTHIAZIDE 40 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| AvKARE | HYDROCHLOROTHIAZIDE 12.5 mg/1; OLMESARTAN MEDOXOMIL 20 mg/1 | Jul 15, 2026 | Jul 19, 2026 |
| Cosette Pharmaceuticals, Inc. | HYDROCHLOROTHIAZIDE 12.5 mg/1; OLMESARTAN MEDOXOMIL 20 mg/1 | Jul 15, 2026 | Jul 19, 2026 |
| AvKARE | HYDROCHLOROTHIAZIDE 12.5 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1 | Jul 15, 2026 | Jul 18, 2026 |
| Cosette Pharmaceuticals, Inc. | HYDROCHLOROTHIAZIDE 12.5 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1 | Jul 15, 2026 | Jul 18, 2026 |
| AvKARE | HYDROCHLOROTHIAZIDE 25 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1 | Jul 15, 2026 | Jul 16, 2026 |
| Cosette Pharmaceuticals, Inc. | HYDROCHLOROTHIAZIDE 25 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1 | Jul 15, 2026 | Jul 16, 2026 |
| Novadoz Pharmaceuticals LLC | HYDROCHLOROTHIAZIDE 12.5 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Novadoz Pharmaceuticals LLC | HYDROCHLOROTHIAZIDE 25 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Novadoz Pharmaceuticals LLC | HYDROCHLOROTHIAZIDE 12.5 mg/1; OLMESARTAN MEDOXOMIL 20 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "olmesartan medoxomil-hydrochlorothiazide — NDC 42291-0926-90," retrieved September 3, 2026, https://drugdashboards.com/drug/42291092690.
Free to cite with attribution — see how the data is put together.